Therapeutic (high) doses of rituximab activate calcium mobilization and inhibit B-cell growth via an unusual mechanism triggered independently of both CD20 and Fcγ receptors

Journal of Immunotherapy

Volumn 33, Issue 1, 2010, Pages 30-39

  Unruh, Tammy L ^a   Zuccolo, Jonathan ^a   Beers, Stephen A ^b   Kanevets, Uliana ^c   Shi, Yan ^a,c   Deans, Julie P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

B cells; Calcium; CD20; IgG; Rituximab

Indexed keywords

CALCIUM; CD20 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; PROTEIN TYROSINE KINASE; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CALCIUM SIGNALING; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOLOGIC FACTORS; RECEPTORS, FC;

EID: 74349096132     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b290f1     Document Type: Article

References (29)

1. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55:477-503.
2. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6:394-403.
3. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6: 859-866.
4. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2-9.
5. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004; 104:2635-2642.
6. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038-1043.
7. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100:1765-1773.
8. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121-2143.
9. Bezombes C, Grazide S, Garret C, et al. Rituximab anti-proliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 2004;104:1166-1173.
10. Cittera E, Onofri C, D'Apolito M, et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother. 2005;54:273-286.
11. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene. 2007;26:3629-3636.
12. Li H, Ayer LM, Lytton J, et al. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 2003;278: 42427-42434.
13. Deans JP, Schieven GL, Shu GL, et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol. 1993;151:4494-4504.
14. Shan D, Ledbetter JA, Press OW. Apoptosis of maligant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
15. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673-683.
16. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26: 133-143.
17. Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139:439-446.
18. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 2002;107:176-182.
19. Unruh TL, Li H, Mutch CM, et al. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology. 2005;116:223-232.
20. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283:16971-16984.
21. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-521.
22. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9: 995-1001.
23. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs Type I (ritux-imab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112:4170-4177.
24. Bootman MD, Collins TJ, Mackenzie L, et al. 2-aminoethox-ydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of InsP3-induced Ca2+ release. Faseb J. 2002;16:1145-1150.
25. Sei Y, Gallagher KL, Basile AS. Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes. J Biol Chem. 1999;274:5995-6002.
26. Pearse RN, Kawabe T, Bolland S, et al. SHIP recruitment attenuates Fc gammaRIIB-induced B cell apoptosis (In Process Citation). Immunity. 1999;10:753-760.
27. Tzeng SJ, Bolland S, Inabe K, et al. The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway. J Biol Chem. 2005;280:35247-35254.
28. Gamberale R, Fernandez-Calotti P, Sanjurjo J, et al. Signaling capacity of FcgammaRII isoforms in B-CLL cells. Leuk Res. 2005;29:1277-1284.
29. Kohler H, Paul S. Superantibody activities: new players in innate and adaptive immune responses. Immunol Today. 1998; 19:221-227.